Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
161
datasets available to search
ShareScore release 0.9.0
Dataset results
161 results for “Drug-eluting stents”
Gender-associated outcomes following percutaneous coronary intervention with a third-generation, ultrathin-strut drug-eluting stent: a real world, single-center experience.
<p>This record contains raw data related to the article: Gender-associated outcomes following percutaneous coronary intervention with a third-generation, ultrathin-strut drug-eluting stent: a real-world, single-center experience.</p> <p>ABSTRACT </p> <p><strong>Introduction.</strong> In recent years the new third-generation, ultrathin bioresorbable-polymer sirolimus-eluting stent (BP-SES), characterized by some of the thinnest struts among commercially available devices (60-80 µm) and an amorphous silicon carbide coating, has been introduced for the treatment of coronary artery disease (CAD). Aim of the present study was to assess different clinical outcomes and safety of this drug-eluting stent in male and female patients in a real-world setting.</p> <p><strong>Methods. </strong>The present study is a retrospective analysis including all patients treated with BP-SES between January 2017 and December 2019 at a single, high-volume center. Follow-up was performed by outpatient visit or by telephone contact. The main study outcome was target lesion failure (TLF), defined as a composite of cardiovascular death, target vessel myocardial infarction or target lesion revascularization.</p> <p><strong>Results: </strong>Overall, 66 (15.9%) female and 349 (84.1%) male patients were included; women were older (median age 70 vs. 66, p=0.003) and with lower BMI (25.0 vs. 26.1, p=0.010) compared to men, with no other relevant differences in baseline characteristics. Indication for percutaneous coronary intervention (PCI) was acute coronary syndrome in 86 (20.7%) of the cases, with no significant differences between male and female patients. A total of 558 lesions were treated with BP-SES stents, 90 in women and 468 in men (1.36 vs. 1.34 lesions per patient, p=0.83); cumulative stent length (33.6 mm vs. 38.4 mm, p=0.078) and mean stent diameter (2.92 mm vs. 3.0 mm, p=0.39) did not differ in women compared to men. Technical and clinical success was achieved in all patients. Stent thrombosis (ST) occurred in 2 (0.5%) patients, both males. TLF occurred in 10 (2.9%) men and in 2 (3.0%) women after a median follow-up of 402 days, without significant differences at log-rank analysis (2.34 events per 100 patient-years in males, 2.53 in females; p=0.80).</p> <p><strong>Conclusions. </strong>Ultrathin struts BP-SES showed a safe and effective option for the treatment of CAD in both women and men, with very low ST rate and favorable long-term outcomes</p>
RESOLUTE Japan - The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent
ClinicalTrials.gov study NCT00927940. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery
ClinicalTrials.gov study NCT00120406. IPD Sharing: Not stated. Countries: 3. Publications: 5.
Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty
ClinicalTrials.gov study NCT01121224. IPD Sharing: NO. Countries: 1. Publications: 3.
ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent
ClinicalTrials.gov study NCT02574481. IPD Sharing: NO. Countries: 7. Publications: 5.
SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries
ClinicalTrials.gov study NCT00114972. IPD Sharing: Not stated. Countries: 18. Publications: 58.
First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease
ClinicalTrials.gov study NCT01247428. IPD Sharing: NO. Countries: 3. Publications: 2.
Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions
ClinicalTrials.gov study NCT00611910. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)
ClinicalTrials.gov study NCT01186146. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
ClinicalTrials.gov study NCT00148356. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents
ClinicalTrials.gov study NCT03507205. IPD Sharing: NO. Countries: 1. Publications: 5.
Quantitative Coronary Angiography Versus Intravascular Ultrasound GUIDancE for Drug-Eluting Stent Implantation
ClinicalTrials.gov study NCT02978456. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
Drug-Coated Balloon in Combination With New Generation Drug-Eluting Stent in the Treatment of Long Diffuse Coronary Artery Disease
ClinicalTrials.gov study NCT05650450. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT)
ClinicalTrials.gov study NCT01674803. IPD Sharing: Not stated. Countries: 1. Publications: 11.
Angiographic Control Vs. Ischemia-driven Management of Patients Treated with PCI on Left Main with Drug-eluting Stents
ClinicalTrials.gov study NCT04144881. IPD Sharing: NO. Countries: 1. Publications: 22.
Percutaneous Coronary Intervention With the Angiolite Drug-eluting Stent: an Optical Cohenrece Tomography Study
ClinicalTrials.gov study NCT02776267. IPD Sharing: UNDECIDED. Countries: 1. Publications: 21.
Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice
ClinicalTrials.gov study NCT01186133. IPD Sharing: UNDECIDED. Countries: 1. Publications: 8.
The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente
ClinicalTrials.gov study NCT01066650. IPD Sharing: Not stated. Countries: 1. Publications: 13.
Optical Coherence Tomography Guided Percutaneous Coronary Intervention for Drug-eluting In-stent Restenosis
ClinicalTrials.gov study NCT03809754. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV: (LONG-DES-IV)
ClinicalTrials.gov study NCT01186094. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.